NasdaqGM - Delayed Quote USD

Aerovate Therapeutics, Inc. (AVTE)

21.75 +0.18 (+0.83%)
At close: April 26 at 4:00 PM EDT
21.75 0.00 (0.00%)
After hours: April 26 at 4:20 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Timothy P. Noyes M.B.A. CEO & Director 936.9k -- 1962
Mr. George A. Eldridge CFO & Treasurer 658.6k -- 1963
Mr. Timothy J. Pigot Chief Commercial Officer 584.6k -- 1971
Dr. Benjamin T. Dake Ph.D. Founder, President, COO & Secretary 435.5k -- 1976
Dr. Marinus Verwijs Ph.D. Chief Technical Officer 439.88k -- 1976
Dr. Ralph W. Niven M.B.A., M.R, Ph.D., Pharm.S Chief Scientific Officer 372.33k -- 1960
Mr. Hunter Gillies M.D. Chief Medical Officer 512.74k -- 1966
Ms. Donna Dea Head of Regulatory Affairs -- -- --
Ms. Susan Fischer Executive Vice President of Development Operations -- -- --
Mr. Stephen K. Yu Senior Vice President of Quality -- -- --

Aerovate Therapeutics, Inc.

930 Winter Street
Suite M-500
Waltham, MA 02451
United States
617 443 2400 https://aerovatetx.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
51

Description

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Corporate Governance

Aerovate Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 8; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 13, 2024 - May 17, 2024
Aerovate Therapeutics, Inc. Earnings Call

Related Tickers

TYRA Tyra Biosciences, Inc.
15.67
+3.71%
 
KROS Keros Therapeutics, Inc.
57.86
+6.77%
 
NAMS NewAmsterdam Pharma Company N.V.
21.99
+2.57%
 
ATXS Astria Therapeutics, Inc.
9.00
-1.85%
 
EWTX Edgewise Therapeutics, Inc.
16.17
+1.44%
 
DNTH Dianthus Therapeutics, Inc.
21.50
+2.43%
 
FULC Fulcrum Therapeutics, Inc.
7.14
+0.14%
 
AVBP ArriVent BioPharma, Inc.
15.44
-0.64%
 
LXEO Lexeo Therapeutics, Inc.
12.50
+2.80%
 
CELC Celcuity Inc.
15.92
+0.95%